MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial

MoonLake Immunotherapeutics has announced positive results from a late-stage Phase 3 clinical trial involving its nanobody drug, sonelokimab, which is designed to treat psoriatic arthritis. According to reporting from Fierce Biotech and Dermatology Times, the drug successfully boosted all clinical endpoints and specifically met its primary end point during the trial process. This development indicates that the treatment reached the key goals necessary for the late-stage trial to be considered successful in its evaluation of efficacy for patients suffering from this specific inflammatory condition. Coverage of the announcement has been widespread across several specialized outlets. Fierce Biotech highlights the success across all clinical endpoints, while Dermatology Times focuses on the achievement of the primary end point.

Market-oriented outlets such as marketscreener.com report that the drug met its key goals. However, FirstWord Pharma notes a contrast in reception, suggesting that while the company is touting the Phase III psoriatic arthritis data, some investors may have expected more significant results than those reported by the company. Parallel to the clinical data, MoonLake Immunotherapeutics has released its financial status for the second quarter of 2026. According to Kalkine Media, the company's Q2 2026 financial results show an increase in net loss. Despite this rise in losses, the report also indicates that the company has increased its cash reserves.

This financial context provides a backdrop for the clinical success, as the company manages the high costs associated with late-stage pharmaceutical development and trial execution while maintaining the capital necessary for future operations. Moving forward, observers will likely monitor how the company leverages these Phase 3 results in the context of its current financial position. While the clinical data for sonelokimab is positive across all tested endpoints, the market reaction described by FirstWord Pharma suggests a period of investor scrutiny. Future updates will likely center on the company's plan for regulatory submission following the successful Phase 3 trial and how the increased cash reserves mentioned by Kalkine Media will be utilized to offset the reported increase in net losses.